Cyclooxygenase-2 Inhibition and Renal Function
Authors: Andrew Whelton
Journal: Annals of Internal Medicine (2001)

Letters5 June 2001Cyclooxygenase-2 Inhibition and Renal FunctionAndrew Whelton, MDAndrew Whelton, MDJohns Hopkins University School of Medicine; Universal Clinical Research Center, Inc. (Whelton)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-11-200106050-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The report by Swan and colleagues (1) defining the effect of a 5-day course or single administration of rofecoxib (a cyclooxygenase-2 [COX-2]–specific enzyme inhibitor) and indomethacin on glomerular filtration rate in 75 "salt-deprived" elderly persons is of interest. Nonetheless, it is not acceptable to conclude that these results for rofecoxib can be generalized to all COX-2–specific inhibitors. The extant data, which were not referenced in the report, indicate that the renal effects of celecoxib and those of conventional nonspecific COX-1 and COX-2 enzyme inhibitors have clinically significant differences. Celecoxib causes lesser edema, smaller glomerular filtration decrements, and ...References1. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al . Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med. 2000;133:1-9. [PMID: 0010877734] LinkGoogle Scholar2. Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PS, Verburg KM, et al . Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465-70. [PMID: 10826459] CrossrefMedlineGoogle Scholar3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al . Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized, controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-55. CrossrefMedlineGoogle Scholar4. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95. [PMID: 11304662] CrossrefMedlineGoogle Scholar5. Dunn MJ. Are COX-2 selective inhibitors nephrotoxic? Am J Kidney Dis. 2000;35:976-7. [PMID: 10793038] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Johns Hopkins University School of Medicine; Universal Clinical Research Center, Inc. (Whelton)Disclaimer: Dr. Whelton is a consultant for G.D. Searle/Pharmacia and Pfizer's COX-2 human development program. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet Suzanne K. Swan , David W. Rudy , Kenneth C. Lasseter , Charles F. Ryan , Kristin L. Buechel , Laurence J. Lambrecht , Manuel B. Pinto , Stacy C. Dilzer , Olga Obrda , Kimberly J. Sundblad , Carol P. Gumbs , David L. Ebel , Hui Quan , Patrick J. Larson , Jules I. Schwartz , Thomas A. Musliner , Barry J. Gertz , D. Craig Brater , and Siu-Long Yao Cyclooxygenase-2 Inhibition and Renal Function Suzanne K. Swan and D. Craig Brater Cyclooxygenase-2 Inhibition and Renal Function Alfred K. Pfister , Robert J. Crisalli , and William H. Carter Metrics Cited ByCyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?Carbonic anhydrase inhibitors for the treatment of neuropathic pain and arthritisRofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspectsModulation of Prostaglandin Biosynthesis by Nitric Oxide and Nitric Oxide DonorsCOX-2 Inhibitors: Effects on Blood Pressure in a Veterans Affairs Medical CenterCyclooxygenase-2 inhibitors: Is there an association with coronary or renal events?COX-2 Inhibitors and Their Role in GynecologyReply 5 June 2001Volume 134, Issue 11Page: 1077-1078KeywordsBlood pressureCyclooxygenase 2EdemaEnzyme inhibitorsGlomerular filtration rateHeart diseasesHypertensionNSAIDsRenal failureSystolic pressure ePublished: 5 June 2001 Issue Published: 5 June 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...